456070.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 13,999,999,610, which is significantly higher than its total liabilities of KRW 24,309,226,940. The current ratio of 13.59 indicates a robust ability to meet short-term obligations. The price-to-book ratio of 3.09 suggests that the market values the company at a premium relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discount.
Profitability metrics are negative, with a return on equity of -40.88% and a return on assets of -25.28%, both significantly below the industry median. The company reported a net loss of KRW 16,107,525,270, and an operating loss of KRW 17,890,496,550, reflecting ongoing operational challenges. Gross profit is also negative at KRW -2,401,953,750, indicating that the cost of goods sold exceeds revenue.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may increase exposure to market-specific risks. The company's revenue concentration is high, with no indication of multiple revenue streams or geographic markets.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. Historical revenue of KRW 5,258,687,310 does not indicate a clear upward or downward trend. The absence of a defined growth strategy or segment-specific outlook complicates the assessment of future performance.
Risk factors include a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.33 suggests a conservative capital structure, and the absence of dilution potential indicates no imminent equity issuance. However, the company's negative operating and net income may necessitate future financing, which could introduce new risks.
Recent events include the latest financial filing, which provides the most recent snapshot of the company's financial position. No recent earnings call transcripts or other material events are available in the provided data. The company's financial performance and strategic direction remain primarily defined by its most recent financial report.
- The company has a strong liquidity position with a current ratio of 13.59 and significant cash reserves.
- Profitability is negative, with a return on equity of -40.88% and a return on assets of -25.28%.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's capital structure is conservative, with a debt-to-equity ratio of 0.33.
- No immediate liquidity or dilution risks are flagged, but the company's negative operating and net income may require future financing.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 456070.KQ Market data — financials · 2026-05-26